Terumo Corp - TRUMY STOCK NEWS

On November 1, 2022, a study published in JAMA showcased that Terumo Health Outcomes' ePRISM software effectively reduced the risk of acute kidney injury (AKI) in high-risk patients undergoing percutaneous coronary interventions. The three-year randomized study involved 31 cardiologists and 7,106 patients, revealing that AKI rates dropped significantly from 51.7% to 38.1% when using ePRISM. The platform’s personalized contrast volume guidelines not only enhance patient care but could also lead to improved hospital performance metrics and reduced healthcare costs.

MicroVention, a subsidiary of Terumo Corporation, has announced the enrollment of its first patient in the STRAIT observational study. This study will assess the BOBBY Balloon Guide Catheter for treating acute ischemic stroke. The BOBBY device, already approved in Europe and North America, aims to enhance balloon preparation and navigability. The first enrollment took place under the guidance of Dr. Tobias Boeckh-Behrens at a Munich facility, where the device was successfully used in a severe stroke case. The trial will provide clinical evidence for BOBBY's effectiveness in improving outcomes.

Terumo Corporation (TSE: 4543) has launched a global Diversity, Equity, and Inclusion (DE&I) Philosophy to enhance workplace culture. The initiative includes a DE&I Guiding Principle to integrate DE&I into all policies and practices. Terumo, operating in over 160 regions, emphasizes the importance of respecting differences among its 26,000 associates, with 70% of revenue generated outside Japan. A Terumo DE&I Week is planned from March 7-11, 2022, featuring management discussions and local events. This aligns with Terumo's upcoming 5-Year Growth Strategy (GS26), aiming for further innovation and healthcare advancements.

Terumo Health Outcomes has entered a collaboration and co-marketing agreement with Corazon, Inc. to enhance cardiovascular care. This partnership focuses on Terumo's ePRISM® platform, which uses algorithms to predict patient outcomes post-cardiac procedures, allowing for improved treatment planning. The collaboration aims to leverage Corazon's accreditation services and Terumo's technology to deliver individualized data analytics, ultimately improving patient outcomes and reducing healthcare costs. Both companies share a commitment to innovation in healthcare delivery.

MicroVention, a Terumo subsidiary, has announced the first U.S. clinical case of its FRED X Flow Diverter device. This device, which received FDA PMA approval in September 2021, utilizes MicroVention X Technology to reduce thrombogenicity and enhance blood vessel healing. It's the first of several devices featuring this technology aimed at improving neurovascular treatments. Approximately 6.5 million Americans have unruptured brain aneurysms, highlighting the potential market impact of the FRED X device. The device is designed for adult patients with specific types of intracranial aneurysms.

Terumo Medical Corporation (TMC) announced its support for updated guidelines from the ACC, AHA, and SCAI, which classify radial access as Class 1 (Level of Evidence A) for percutaneous coronary intervention (PCI) in acute coronary syndrome and stable ischemic heart disease patients. This endorsement is expected to enhance the adoption of radial access, known for reducing access-site complications, promoting early ambulation, increasing patient satisfaction, and potentially improving financial outcomes. Terumo celebrates its 30-year legacy in radial access innovation and education.

Terumo Blood and Cell Technologies and PhotonPharma have agreed to collaborate on developing Innocell, a new tumor-specific immunotherapy for solid tumors. This partnership aims to expedite the treatment's market entry and includes Terumo's Mirasol Pathogen Reduction Technology in the manufacturing process. The FDA will support PhotonPharma's regulatory submission using Mirasol's Device Master File. This MOU lays the groundwork for further development and commercialization of Innocell, with a focus on triple-negative breast cancer. This collaboration could significantly benefit patients facing cancer.